Division of Eye and Vision
The Division of Eye and vision which is located at St. Erik Eye Hospital, conducts education at the undergraduate, advanced and postgraduate levels, as well as research with the aim of developing the eye care of the future.
Menu for this area
Research seminars and dissertations
Research seminar, April 17
Speaker: Arnold Wilkins, University of Essex
Title: Stripes can be bad for you
12.00 at Studenttorget, floor 1. St. Erik Eye Hospital.
Lunch sandwich will be served from 11.50.
Research seminars
May 14, Research seminar - Research group Kvanta/André
Latest news
Research grant for a doctoral position from Promobilia
Yiting Wang has been awarded a research grant for a doctoral position by the Promobilia Foundation (Doctoral Fellowship) amounting to 1 450 000 SEK. The grant covers a period of two years with the possibility of extension for an additional two years with the same amount.
Yiting Wang is an engineer in electrical and computer engineering, specializing in machine learning and AI. In this project, we will explore the possibility that so-called fixational eye movements and microsaccades – a type of very small, rapid, and involuntary eye movements that are relatively unexplored in clinical contexts – may carry information about brain health that can help us detect symptoms of early-stage Parkinson's disease.
Generous donation to eye research at KI
The Ulla and Ingemar Dahlberg Foundation has decided to donate SEK 50 million to Karolinska Institutet. The grant will be used for a new professorship in vision science with a focus on ocular neurobiology and have the full name "Ulla och Ingemar Dahlbergs professur i synvetenskap med inriktning mot okulär neurobiologi" (Ulla and Ingemar Dahlberg's Professorship in Visual Science with specialization in Ocular Neurobiology).
"It's an incredibly important and welcome donation. KI generally has a relatively small number of professors in ophthalmology, so this addition will make a big difference to eye research in Sweden," says Rune Brautaset, professor at the Department of Clinical Neuroscience and head of the Division of Eye and Vision.
KI Innovations brings in 6 new companies into the incubator - strengthening in Medtech and drug development
KI Innovation's Deeptech incubator DRIVE expands its portfolio by bringing in six new companies with a focus on the development of pharmaceuticals, cell therapies, diagnostics and Medtech products. With the right support, the accepted companies all have great potential to contribute to the benefit of society. Pete Williams and Melissa Jöe from Pete Williams' research group with Mim Neuroscience are one of the selected companies.
Physiological optics
He looks at brain disorders through the retina
With the help of OCT analysis, there is a simple and inexpensive way of examining the eyes in order to monitor the progression of disease and effect of treatment in people with multiple sclerosis (MS).
We can do this since loss of nervous tissue in the brain is reflected in the retina, says Optometrist and researcher Rune Brautaset who uses OCT for his research.
Repeatability of a fully automated swept-source optical coherence tomography biometer and agreement with a low coherence reflectometry biometer
In conclusion, our results demonstrate that the Eyestar 900 and Lenstar LS 900 provide repeatable measurements for the different parameters analyzed. Comparing the instruments, we believe that despite the statistically significant differences reported in CCT and LT and the LoA values, we consider them negligible from a clinical standpoint. Hence, the two biometers can be used interchangeably.
The integrity of psychophysical visual function in non-immunocompromised PLHIV (NIPLHIV) without retinitis on antiretroviral therapy (ART)
The present study investigated the integrity of contrast sensitivity (CS), colour vision, and pattern evoked vision potentials (VEP) in non-immunocompromised people living with HIV (NIPLHIV) without retinitis.
The Integrity of Retinal Morphology in Non-immunocompromised People Living with HIV on Antiretroviral Therapy
Macula thickness and volumetric differences do exist in NIPLHIV. Practitioners should keep NIPLHIV under retinal morphometric surveillance because they live longer. Associations of cerebral atrophy with retinal morphology may be used to monitor cerebral atrophy in NIPLIV on ART.
Optical Coherence Tomography Can Predict Visual Acuity in Children with Optic Nerve Hypoplasia
OCT can facilitate the diagnosis of ONH. Parameters such as pRNFL, GCC and BMO can be predictors of visual acuity whereas GCC and pRNFL thinning can indicate location and severity of visual field defects.
Optical Coherence Tomography Identifies Visual Pathway Involvement Earlier than Visual Function Tests in Children with MRI-Verified Optic Pathway Gliomas
Retrograde degeneration of the eye’s retinal ganglion cells, causing visual loss and even blindness, is a feared consequence of optic pathway gliomas. Optical coherence tomography (OCT) is a patient-friendly, high-resolution imaging technique enabling objective measurements of the integrity of the retinal ganglion cell layer.
Agreement of different OCT scan directions for individual retinal-layer thickness measurements in multiple sclerosis subjects with prior unilateral optic neuritis
The similarities between horizontal and vertical Optical Coherence Tomography (OCT) scans for the individual retinal layer thickness measurements in the macula was evaluated. The larger limit of agreement intervals seen for different layers and sectors suggests that the scan direction must be same for the follow-up OCT measurements and in clinical studies.
The relationship between retinal structure and visual function in non-immuno-compromised people living with HIV without retinitis on antiretroviral therapy
The recognition of associations may be the first step in the proposal to develop a framework for the surveillance of vision in patients with NIPLHIV. We recommend a study of the sample population to track the stability of these observations before general recommendations for clinical care.
Structural impact of arrested foveal development in children born extremely preterm without ROP at 6.5 years of age
Extreme prematurity without impact of ROP is associated with increased GCL + , ONL, and RT thickness at FC as well as reduced FD compared to full-term controls at age 6.5. This indicates that prematurity per se may have a profound effect on foveal anatomical maturation during the first months after birth. Our results suggest RT at FC to be a simple and useful measure of foveal anatomical immaturity.
Retina
KI researchers Anders Kvanta and Fredrik Lanner awarded a SEK 10 million grant
The Erling-Persson Foundation has awarded Anders Kvanta, professor at the Department of Clinical Neuroscience, Karolinska Institutet, and Fredrik Lanner, senior researcher at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet, a research grant of SEK 10 million extending over three years.
Doctoral funding from KI strengthens research on lack of oxygen in the eye tissue
Research group leader Helder André at St. Erik Eye Hospital and Karolinska Institutet has been awarded funds from KI's special grant for training a doctoral candidate. The funding enables the employment of a doctoral student for the project The translational role of hypoxia in blinding neovascular diseases for four years.
Transplantation of vision cells made from embryonic stem cells can restore lost vision
A new study published in the scientific journal Molecular Therapy, shows that transplanted vision cells made from embryonic stem cells can restore vision.
Clinically transplantable photoreceptors researcher recruited thanks to philanthropic donation
A private philanthropic donation has made it possible for St. Erik Eye Hospital to finance the Karolinska Institutet appointment of stem cell researcher David Brenière-Letuffe.
Eye research expands when research group is split
Eye research at St. Erik Eye Hospital and Karolinska Institutet is advancing when the existing research group in retina and ocular oncology is divided into two to refine the research lines. Ophthalmologist and Associate Professor Gustav Stålhammar and researcher Helder André step in as new research group leaders.
One million in grants for age-related macular degeneration researcher Helder André
Helder André, research group leader at St. Erik Eye Hospital and at Karolinska Institutet, is awarded one million kronor from the ARMEC Lindeberg Foundation for his research project Novel Gene Therapy Strategies for the Sustainable Treatment of Age-related Macular Degeneration.
Ocular Oncology and Pathology
Improved Staging of Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume and Competing Risk Analyses
Eye specialist and cancer researcher Gustav Stålhammar, together with researchers at St. Erik's Eye Hospital and the Karolinska Institutet, in an international collaboration, has developed a new and better classification of the aggressive eye cancer uveal melanoma. The study is published in the respected journal Ophthalmology.
Gustav Stålhammar, nominated as one of the emerging and promising young researchers from the Nordic countries.
Acta Board have been nominated Gustav Stålhammar as one of the emerging and promising young researchers from the Nordic countries.
followed by a session with four young speakers from the Scandinavian countries, each of whom will talk about their own research. We invite you to be one of these speakers.
On the occasion of the 100th of Acta anniversary in Maastricht in June, Gustav is invited together with Joni Turunen, Finland och Cecilie Bredrup, Norway to speak about their own research.
Title of Gustavs lecture is: ”Uveal melanoma past, present, and future -Towards adjuvant treatment”
Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit
Vi visar att 4 av 5 bröstcancermetastaser i ögonen och orbita är av typen Luminal B, och att fler än hälften är positiva för HER2.
Vidare ser vi även att subtypen av bröstcancer ofta ändras mellan primärtumören i bröstet och metastasen i ögat.
Start of large clinical study of melatonin against uveal melanoma
In a clinical study involving about a hundred patients with uveal melanoma, researchers at St. Erik Eye Hospital will test whether an additional treatment with melatonin can prevent the development of metastases.
The study has a planned duration of up to ten years.
He does research with the aim to reduce mortality from eye tumours
Unlike most other types of cancer, the survival in ocular melanoma has not improved in several decades. This is something that eye specialist and researcher Gustav Stålhammar wants to change.
"It is time we give this disease a fight. We need to investigate if it’s better to prevent the development of metastases rather than treating them once they appear", he says.
Study confirms inflammation of the eye with glaucoma
A study at St Erik Eye Hospital and Karolinska Institutet is now able to confirm that inflammation of the retina and optic nerve occurs in patients with glaucoma. The results are published in the journal Acta Neuropathologica Communications.
Eye research expands when research group is split
Eye research at St. Erik Eye Hospital and Karolinska Institutet is advancing when the existing research group in retina and ocular oncology is divided into two to refine the research lines. Ophthalmologist and Associate Professor Gustav Stålhammar and researcher Helder André step in as new research group leaders.
Prognostic implications of tenascin C in peripheral blood and primary tumours at the time of uveal melanoma diagnosis
To examine the prognostic implication of tenascin C (TNC) in posterior uveal melanoma (UM).
Conclusions: TNC is a prognostic biomarker in UM. At the time of primary tumour diagnosis, it is measured in higher levels in both peripheral blood and tumour tissue from patients who will eventually suffer from metastatic death.
The prognostic implication of visual acuity at the time of uveal melanoma diagnosis
What was known before
Visual outcomes after treatment of uveal melanoma have been investigated repeatedly. Surprisingly few studies have examined the correlation between visual acuity before primary tumour treatment with long-term patient outcomes.
What this study adds
In a cohort of 1809 patients, we find that uveal melanoma patients with low visual acuity before treatment have greater incidence of uveal-melanoma-related mortality in competing risk analysis, and that they have shorter overall survival. This is likely related to the fact that patients with low visual acuity had significantly larger tumours. In the second cohort with 137 enucleated eyes, however, there were no significant relations between low visual acuity and any one of 13 examined tumour histological factors at a Bonferroni-corrected significance level.
Delays Between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death
Increasing time between diagnosis and treatment of uveal melanoma is associated with a higher risk of metastatic death. These results challenge a central concept in the understanding of metastatic progression and may indicate the existence of late metastatic seeding. They also underscore the importance of prompt treatment. Validation in independent cohorts is recommended.
Digital morphometry and cluster analysis identifies four types of melanocyte during uveal melanoma progression
Four basic cell types can be outlined in uveal melanoma progression: normal, spindle A and B, and epithelioid. Differential expression of tumor suppressors, growth factors, and immune checkpoints could contribute to their relative over- and underrepresentation in benign, primary tumor, and metastatic samples.
Sex-based differences in early and late uveal melanoma-related mortality
Women with uveal melanoma have better survival in the first decade after diagnosis. Thereafter, female survivors are significantly older than men and have a higher incidence of uveal melanoma-related mortality.
No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter
To assess the long-term prognosis for patients with iris melanomas and compare it with the prognosis for small choroidal melanomas.
Gain of Chromosome 6p Correlates with Severe Anaplasia, Cellular Hyperchromasia, and Extraocular Spread of Retinoblastoma
Ökning av antalet kopior av kromosom 6 i Retinoblastom ökar risken för spridning av tumören utanför ögat. I ett samarbete mellan två amerikanska universitet och forskare från S:t Eriks Ögonsjukhus har man kartlagt hur antalet kopior av den korta armen av kromosom 6 korrelerar med risken för att Retinoblastom ska sprida sig utanför ögat.Gustav Stålhammar, specialistläkare i ögonsjukdomar och patologi, och docent vid Karolinska Institutet, var huvudansvarig för studien.
Risk for Acute Myocardial Infarction After Ophthalmologic Procedures
Do surgeries lead to an increased risk of heart attack?The simple answer is no. New study in Annals of Internal Medicine.
The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis
Among the exceedingly rare published patients with untreated primary uveal melanoma, 80–90% have developed metastases and their disease-specific survival seems to be shorter than treated patients. This could indicate that some metastases might be prevented by primary tumor treatment.
Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma
Compared with 20-mm plaques, brachytherapy with 15-mm ruthenium plaques is associated with a higher risk for tumor recurrence and death. These adverse outcomes may be avoided by increasing safety margins and implementing effective methods to verify accurate plaque positioning.
Obesity paradox in uveal melanoma: high body mass index is associated with low metastatic risk
Metabolic factors and obesity may influence the development and progression of cancer. In this study, we examine their association with the risk of developing metastases of uveal melanoma.
Conclusion; Obesity and elevated serum leptin levels are associated with a lower risk for developing metastases and dying from uveal melanoma.
Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases
We demonstrate multiorgan involvement of apparently dormant micrometastases in patients with uveal melanoma. This suggests that micrometastases are present in nearly all patients diagnosed with primary uveal melanoma, regardless of coexisting macrometastases.
A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival
A prognostic test based on a single peripheral venous blood sample at the time of uveal melanoma diagnosis stratifies patients into low, intermediate, and high metastatic risk categories. Prospective validation will facilitate its clinical utility.
Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study
In this trial, 100 subjects with non-metastatic uveal melanoma will be randomized to either treatment with melatonin 20 mg at 10 pm for 5 years or to a control group. The main objective is to investigate whether treatment with melatonin can reduce the risk of developing metastases after 5 years. Only subjects at high risk for metastasis development will be included in the trial. As uveal melanoma has a relatively low incidence rate compared to other cancers, the recruitment period is estimated to take 3 to 4 years.
Eye movements and vision
A novel view on the role of vision in brain injury
Each year tens of thousands of Swedes suffer from concussion. Some of them experience persistent difficulties, such as brain fatigue, sensitivity to light, headache and problems focusing. Optometrist and Research Group Leader Tony Pansell researches the benefits of spectacle treatment and vision therapy in this context.
Vision impairment is common in non-hospitalised patients with post-COVID-19 syndrome
Vision-related symptoms and impairments were prevalent in the study group. The Developmental Eye Movement Test and the Visual Motion Sensitivity Clinical Test Protocol showed promise for clinical assessment of saccadic performance and sensitivity to movement in the environment. Further study will be required to explore the utility of these tools.
Translation and validation of a Swedish version of the Visual Vertigo Analogue Scale
The present study aimed to construct and validate a Swedish translation (VVAS-S) of the Visual Vertigo Analogue Scale (VVAS).
The Swedish version of the Visual Vertigo Analogue Scale is a questionnaire suitable for evaluating visually induced dizziness in a Swedish population. This study found that the Swedish questionnaire was comparable to the original in terms of internal consistency. The Swedish Visual vertigo Analogue Scale can be found as an appendix to this article.
Concussed patients with visually induced dizziness exhibit increased ocular torsion and vertical vergence during optokinetic gaze-stabilization
Visually Induced Dizziness (VID) is a common post-concussion sequalae that remains poorly understood and difficult to quantify. The present study aims to identify biomarkers for VID in the form of gaze-stabilizing eye movements. Nine patients with post-commotio VID and nine age-matched healthy controls were recruited by physiotherapists at a local neurorehabilitation centre.
In conclusion, post-commotio VID was associated with faster slow-phases during optokinetic gaze-stabilization, with both vergence and torsion being correlated to symptom intensity. As torsional tracking remains inaccessible using commercial eye-trackers, vertical vergence may prove particularly accessible for clinical utility.
The prognostic implication of visual acuity at the time of uveal melanoma diagnosis
What was known before
Visual outcomes after treatment of uveal melanoma have been investigated repeatedly. Surprisingly few studies have examined the correlation between visual acuity before primary tumour treatment with long-term patient outcomes.
What this study adds
In a cohort of 1809 patients, we find that uveal melanoma patients with low visual acuity before treatment have greater incidence of uveal-melanoma-related mortality in competing risk analysis, and that they have shorter overall survival. This is likely related to the fact that patients with low visual acuity had significantly larger tumours. In the second cohort with 137 enucleated eyes, however, there were no significant relations between low visual acuity and any one of 13 examined tumour histological factors at a Bonferroni-corrected significance level.
Visual outcome, ocular findings, and visual quality of life in patients with Fabry disease
BCVA in FD-patients was good despite corneal and lens pathology. Ocular variables did not show an association with TSS in adult patients.
Corneal or lens opacities should also lead to a suspicion of FD in children.
Optical Coherence Tomography Identifies Visual Pathway Involvement Earlier than Visual Function Tests in Children with MRI-Verified Optic Pathway Gliomas
Retrograde degeneration of the eye’s retinal ganglion cells, causing visual loss and even blindness, is a feared consequence of optic pathway gliomas. Optical coherence tomography (OCT) is a patient-friendly, high-resolution imaging technique enabling objective measurements of the integrity of the retinal ganglion cell layer.
Conserved subcortical processing in visuo-vestibular gaze control
Gaze stabilization compensates for movements of the head or external environment to minimize image blurring. Multisensory information stabilizes the scene on the retina via the vestibulo-ocular (VOR) and optokinetic (OKR) reflexes. While the organization of neuronal circuits underlying VOR is well-described across vertebrates, less is known about the contribution and evolution of the OKR and the basic structures allowing visuo-vestibular integration. To analyze these neuronal pathways underlying visuo-vestibular integration, we developed a setup using a lamprey eye-brain-labyrinth preparation, which allowed coordinating electrophysiological recordings, vestibular stimulation with a moving platform, and visual stimulation via screens.
Neurodevelopmental disorders and somatic diagnoses in a national cohort of children born before 24 weeks of gestation
The study showed that 75% of infants born EPT, before 24 weeks of gestation, were affected by neurodevelopmental disorders during childhood and 88% had somatic disorders. The most common issues included asthma and childhood bronchopulmonary dysplasia, speech disorders, intellectual disabilities, failure to thrive, ADHD and ASD. Boys were more likely to have intellectual disabilities than girls.
Glaucoma
Pete Williams is awarded 3 MSEK from StratNeuro for eye treatment with nanotechnology
Pete Williams, associate professor and research group leader at Karolinska Institutet and St. Erik Eye Hospital, has been awarded 3 MSEK from the Strategic Research Area Neuroscience (StratNeuro) at Karolinska Institutet to develop methods for delivering neuroprotective drugs to the eye using nanocarriers.
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering
James Tribble and Pete Williams have written a comprehensive review article highlighting the progress of research into new glaucoma treatments. The article, written with colleagues in Australia and Canada, offers a perspective on non-IOP lowering treatments for glaucoma focusing on both pre-clinical and clinical research. In particular, the team discusses the rapid advancement in understanding of metabolic dysfunction in the retina in glaucoma.
-We hope that this article will be an excellent starting point for scientists and clinicians entering the research field as well as an important resource for those wishing to learn more about where the future of glaucoma management may lie.
Pete Williams receives 400,000 from Hedlund Foundation
Researcher Pete Williams receives 400,000 from the Hedlund Foundation for evaluation of new NAD-generating drugs to prevent neurodegeneration. The research group is mechanistically testing NAD-regulation in sensory neuron health and disease using the model organism C. elegans.
Glaucoma researcher Pete Williams is awarded the 2023 Pfizer Ophthalmics Carl Camras Translational Research Award
Pete Williams and his research team have focused on studying and understanding the changes in the eye that lead to glaucoma rather than managing the risk factors. Several studies on how nicotinamide (a variant of vitamin B) can slow down the degenerating processes and protect the optic nerve have led to the start of a larger clinical study in the spring of 2022.
Glaucoma affects millions of people. Could a readily available vitamin supplement help?
Glaucoma involves the gradual loss of the nerve cells in the eye — the retinal ganglion cells — which provide communication between the eye and the brain so we can see.
Pete Williams and his team found that as we got older, our eyes create less NAD, leaving the retinal ganglion cells potentially starved of energy. Dr Williams and his team found that nicotinamide supplementation prevented a lot of the nerve damage in the mice that would typically appear with glaucoma.
Broad overview published on strategies to protect neurons in glaucoma
James Tribble, Assistant Professor at Karolinska Institutet and St. Erik Eye Hospital, has written an overview article with colleagues in Australia and Canada on how research into new glaucoma treatments is progressing.
Glaucoma research receives grant from the Glaucoma Research Foundation
James Tribble, Assistant Professor at Karolinska Institutet and St. Erik Eye Hospital, has been granted 0,5 MSEK from the Glaucoma Research Foundation. In this one year project, James Tribble’s lab will identify ways to turn down damaging inflammation that can occur in the retina in glaucoma as nerve cells become dysfunctional and break down.
Glaucoma research receives 4,8 MSEK grant from the Swedish Research Council
Pete Williams, Associate Professor at Karolinska Institutet and St. Erik Eye Hospital, has been granted 4,8 MSEK from the Swedish Research Council.
Over the next four years, Pete Williams' research group will develop protective treatments for the nerve cells that are broken down in glaucoma and other eye diseases, focusing on the metabolism of the NAD, an important metabolite for the health of the neuron.
Study confirms inflammation of the eye with glaucoma
A study at St Erik Eye Hospital and Karolinska Institutet is now able to confirm that inflammation of the retina and optic nerve occurs in patients with glaucoma. The results are published in the journal Acta Neuropathologica Communications.
Large clinical study on promising potential glaucoma treatment to begin this spring
In the spring of 2022, researchers at Umeå University, Karolinska Institutet, and St. Erik Eye Hospital will begin a large clinical study on nicotinamide (a form of vitamin B3) as a neuroprotective agent in glaucoma. In the longer term, the study could result in a new form of treatment for glaucoma.
We are very pleased to have reached this stage where we will evaluate the effectiveness of nicotinamide supplementation. If the treatment also shows the long-term effects we are hoping for, it will be an extremely important finding for glaucoma patients, says Pete Williams, associate professor and research group leader at Karolinska Institutet and St. Erik Eye Hospital.
Alcon USD 75,000 grant awarded to glaucoma researcher Pete Williams
Assistant Professor and Research Group Leader Pete Williams at St. Erik Eye Hospital and Karolinska Institutet has been appointed the 2021 Alcon Research Institute (ARI)
Researchers propose a new way to discover new glaucoma treatments
In a study recently published in the Journal of Clinical Medicine, researchers at Karolinska Institutet and St. Erik Eye Hospital, present a new way of identifying potential therapeutics based on exploring common genetic changes in models of glaucoma. The study showed that by using this approach, multiple glaucoma-relevant therapies could be pre-clinically tested. Enhancing the ability to identify potential therapeutics is vital for improving patient outcomes in the future.
Shorter path to new treatments
The research facilities in the new St. Erik Eye Hospital are now fully functional for researchers at St. Erik/Karolinska Institutet. The environment aims to provide optimal conditions for translating the research results faster and more efficiently from basic research to clinical reality for the patients.
New study on vitamin B₃ as a possible treatment for glaucoma
Glaucoma involves a high risk of losing sight. Researchers at Karolinska Institutet and St. Erik Eye Hospital, among others, have now studied the effects of nicotinamide, the amide of vitamin B₃, on animal and cell models for glaucoma. The study, published in Redox Biology, may be a future neuroprotective therapy in glaucoma in humans. A clinical trial will start in the autumn.
New knowledge about hyaluronic acid may help patients with severe dry eye disease
High molecular weight hyaluronic eye drops 0.15 per cent, provided superior improvement of symptoms in patients with severe dry eye disease, when compared to other lubricant eye drops. This is the result of a clinical study from 2016–2020 published in the Journal of Clinical Medicine, coordinated by Ophthalmologist and Docent Gysbert van Setten at St. Erik Eye Hospital and Karolinska Institutet.
Glaucoma researcher Pete Williams is awarded the Axel Hirsch Prize 2021
Assistant Professor and Research Group Leader Pete Williams at Karolinska Institutet and St. Erik Eye Hospital receives the Axel Hirsch Prize 2021. He is awarded for his groundbreaking studies on glaucoma and the discovery that metabolic dysfunction casues mitochondrial abnormalities and neurodegeneration in patients with glaucoma.
Prophylactic nicotinamide treatment protects from rotenone-induced neurodegeneration by increasing mitochondrial content and volume
Leber’s hereditary optic neuropathy (LHON) is driven by mtDNA mutations affecting Complex I presenting as progressive retinal ganglion cell dysfunction usually in the absence of extra-ophthalmic symptoms. There are no long-term neuroprotective agents for LHON. Oral nicotinamide provides a robust neuroprotective effect against mitochondrial and metabolic dysfunction in other retinal injuries. We explored the potential for nicotinamide to protect mitochondria in LHON by modelling the disease in mice through intravitreal injection of the Complex I inhibitor rotenone.
Large VR clinical grant
Gauti Jóhannesson, Associate Professor and Chief Physician at the Department of Clinical Sciences, receives SEK 19,964,000 over the four-year period 2024 – 2027 for the project Neuroprotective treatment of glaucoma – A clinical randomized trial for evaluation of nicotinamide
Karolinska Institutet/ St. Erik's Eye Hospital is one of the clinics participating in the study The Swedish Glaucoma Nicotinamide Trial SGNT ww.sgnt.se
Nicotinamide Prevents Retinal Vascular Dropout in a Rat Model of Ocular Hypertension and Supports Ocular Blood Supply in Glaucoma Patients
Conclusions: Nicotinamide (NAM) can prevent retinal vascular damage in an animal model of glaucoma. After NAM treatment, glaucoma patients and healthy controls demonstrated a small increase in retinal vessel parameters as assessed by OCTA.
NAD salvage pathway machinery expression in normal and glaucomatous retina and optic nerve
These findings demonstrate that the inner retina and optic nerve head is highly enriched with the machinery to directly utilize nicotinamide through the salvage pathway and that the ability to do so is maintained, but the capacity to do so may be lower in glaucoma.
Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma
A combination of nicotinamide and pyruvate yielded significant short-term improvement in visual function, supporting prior experimental research suggesting a role for these agents in neuroprotection for individuals with glaucoma and confirming the need for long-term studies to establish their usefulness in slowing progression.
125 000 SEK to James Tribble from Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för synskadade.
James Tribble, Assistant Professor, Research group Williams got awarded 125 000 SEK from Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för synskadade.
This grant contributes to the Tribble lab’s ongoing research into neuroinflammation in glaucoma with a particular focus on the role of Galectin-3. - This project will identify how targeting Galectin-3 may influence the inflammatory profile of the cells of the retina, and how targeting it may provide neuroprotection in glaucoma.
Diploma for best essay has been awarded to: Albin Camitz and supervisor James Tribble from research group Williams
The paper was chosen by the course's examiners and coordinators from a total of 165 students who took the course vt23. https://utbildning.ki.se/student/examensarbete-i-medicin-diplom-for-basta-uppsats/2lk028
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium
Retinal ganglion cell (RGC) death in glaucoma and other optic neuropathies results in irreversible vision loss due to the mammalian central nervous system’s limited regenerative capacity. RGC repopulation is a promising therapeutic approach to reverse vision loss from optic neuropathies if the newly introduced neurons can reestablish functional retinal and thalamic circuits.
The RReSTORe Consortium
Pete Williams and James Tribble have been part of a consortium to protect, regenerate, and repopulate the optic nerve and the retina as senior investigator
Goals of the consortium are to define and prioritize the most critical challenges and questions related to RGC regeneration over the next five years and to brainstorm innovative tools and experimental approaches to meeting these challenges while fostering opportunities for collaborative scientific investigation among diverse investigators.
Valproic Acid Reduces Neuroinflammation to Provide Retinal Ganglion Cell Neuroprotection in the Retina Axotomy Model
The retinal explant model is a useful tool to explore resident neuroinflammation. Neuroinflammation can be modulated and explored on a rapid timescale whilst maintaining a complex system of cell interactions. VPA can attenuate resident glial inflammation in the retina and is a useful tool to further explore inhibition of pro-inflammatory glia in neurodegenerative disease.
Study confirms inflammation of the eye with glaucoma
A study at St Erik Eye Hospital and Karolinska Institutet is now able to confirm that inflammation of the retina and optic nerve occurs in patients with glaucoma. The results are published in the journal Acta Neuropathologica Communications.